Ketamine's antidepressant effect is a result of the enhancement of Kcnq2 potassium channels in a certain subtype of glutamate-sensitive neurons.
Ezogabine, a drug that opens up the KCNQ2/3 type potassium channel, significantly improved symptoms of depression and anhedonia.
GABA can selectively regulate the excitability of neurons.
Ezogabine, an FDA approved anti-convulsant, appears to significantly reduce symptoms in those with major depressive disorder.
Researchers have discovered a molecular chain of events that enable cells in the inner ear to practice processing sounds during development.
Researchers discover changes in the activity of sodium and potassium channels during the day and night impact the sleep-wake cycle.
Researchers report a new drug could treat epilepsy and help prevent tinnitus by selectively affecting potassium channels.
A new study reports researchers have used whole genome sequencing to identify a new genetic cause of epileptic encephalopathy.
A study suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought. In a second study, the researchers identified the molecular pathway in SMA that leads to problems with motor function.
